Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations

Gene Therapy

Volumn 14, Issue 8, 2007, Pages 699-703

  Metzner, A ^a   Horstmann, M A ^b   Fehse, B ^c   Ortmeyer, G ^a   Niemeyer, C M ^d   Stocking, C ^e   Mayr, G W ^a   Jucker M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Pediatric Hematology and Oncology ^*  (Germany)

^c Bone Marrow Transplantation Center   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN KRAS 2; PROTEIN PTPN 11; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE; RAS PROTEIN; RETROVIRUS VECTOR; SH2 CONTAINING INOSITOL 5 PHOSPHATASE 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLONOGENIC ASSAY; GENE EXPRESSION; GENE TRANSFER; HUMAN; IMMUNOREGULATION; JUVENILE MYELOMONOCYTIC LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FLOW CYTOMETRY; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFANT, NEWBORN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TRANSDUCTION, GENETIC;

MUS;

EID: 34247137233     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302912     Document Type: Article

References (20)

1. Liu L, Damen JE, Ware M, Hughes M, Krystal G. SHIP, a new player in cytokine-induced signalling. Leukemia 1997; 11: 181-184.
2. Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function and biology of SHIP proteins. Genes Dev 2000; 14: 505-520.
3. Helgason CD, Damen JE, Rosten P, Grewal R, Sorrensen P, Chappel SM et al. Targeted disruption of SHIP leads to hemapoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998; 12 1610-1620.
4. Liu Q, Sasaki T, Kozieradzki I, Wakeham A, Itie A, Dumont DJ et al. SHIP is a negative regulator of growth factor receptormediated PKB/ Akt activation and myeloid cell survival. Genes Dev 1999; 13 786-791.
5. Luo JM, Liu ZL, Hao HL, Wang FX, Dong ZR, Ohno R. Mutation analysis of SHIP gene in acute leukemia. J Exp Hematol 2004; 12: 420-426.
6. Luo JM, Yoshida H, Komura S, Ohishi N, Pau L, Shigeno K et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003; 17: 1-8.
7. Horn S, Endl E, Fehse B, Weck MM, Mayr GW, Jucker M. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK3β signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 2004; 18: 1839-1849.
8. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77: 925-929.
9. Lapidot T, Grunberger T, Vormoor J, Estrov Z, Kollet O, Bunin N et al. Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice. Blood 1996; 88: 2655-2664.
10. + cells: Aberrant growth and differentiation properties. Stem cells 1996; 14: 690-701.
11. Iversen PO, Lewis ID, Turczynowicz S, Hasle N, Niemeyer C, Schmiegelow K et al. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood 1997; 90: 4910-4917.
12. Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J et al. Ras mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999; 13: 32-37.
13. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148-150.
14. Side L, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92: 267-272.
15. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EMBT trial. Blood 2005; 105: 410-419.
16. Niemeyer CM, Fenu S, Hasle H, Mann G, Stary J, Van Wernig E. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998; 91: 365-367.
17. Schwieger M, Löhler J, Friel J, Scheller M, Horak I, Stocking C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 2002; 196: 1227-1240.
18. Cosset F-L, Takeuchi Y, Battini J-L, Weiss RA, Collins MK. High titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
19. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstrasser E, Emanuel PD et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005; 106: 2183-2185.
20. Lord E. The use of the range in place of standard deviation in the t test. Biometrika 1947; 34: 41-67.